Imukin (Recombinant Human Interferon Gamma 1b)

The active protein binds to interferon‑gamma receptors on immune cells, triggering the JAK‑STAT pathway. This activation enhances macrophage microbicidal activity, improves antigen presentation, and promotes Th1 immune responses, while also stimulating osteoclast differentiation to normalize bone turnover.

The dosing regimen for Imukin is individualized by the prescribing physician based on the patient’s weight, disease severity, and clinical response. Healthcare providers determine the appropriate dose and administration schedule according to current medical guidelines.

Safety data for Imukin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Imukin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imukin (interferon‑gamma) specifically activates macrophages and promotes Th1 responses, whereas other immunostimulants like interferon‑alpha primarily enhance antiviral defenses. The choice depends on the underlying disease; interferon‑gamma is the preferred agent for conditions such as chronic granulomatous disease and osteopetrosis.

Imukin must be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain product stability.

Imukin is given as a subcutaneous injection, typically by a healthcare professional. The injection site should be rotated, and aseptic technique must be followed to reduce the risk of infection or local reactions.

Serious adverse events can include hematologic abnormalities such as anemia or leukopenia, liver enzyme elevations, autoimmune reactions, severe allergic responses including anaphylaxis, and pulmonary complications like interstitial pneumonitis. Prompt medical evaluation is required if any of these occur.

Imukin is contraindicated in patients with known hypersensitivity to interferon‑gamma or any excipients in the formulation. Caution is also advised for individuals receiving live vaccines, those with uncontrolled autoimmune disease, or patients with severe hepatic impairment, unless a specialist determines the benefits outweigh the risks.